CELG CELGENE CORPORATION

$108.24
$0.00 (0.00%)

CELG Stock Analysis Overview

No Overall Rank data available for CELGENE CORPORATION (CELG)

Create a FREE account to see full CELG report

CELGENE CORPORATION (CELG) Analyst Forecast

Next 12 months ➝Current Price$108.2452-week High$110.7052-week Low$58.59MEAN$97.00-10.38%HIGH$115.00+6.25%LOW$77.00-28.86%
  • Last Price$108.24
  • Previous Close$108.24
  • Change $0.00
  • Open$108.01
  • Volume0
  • Avg. Volume (100-day)6,072,541
  • Market Capitalization$77B
  • Days Range
  • 52-week Range $58.59 - $110.70
  • Dividend Yield
  • Ex. Dividend Date
  • P-E
  • EPS
  • Earnings Date04/29/2020
  • SectorHealthcare
  • IndustryDrug Manufacturers - General
  • Avg. Analyst Rec.
  • Beta
  • PEG Ratio0.52
  • Volatility
  • Average True Range
Celgene is a biopharmaceutical firm that discovers, develops, and markets therapeutics for the treatment of cancer and immunological diseases. Celgene markets Thalomid and Pomalyst to treat multiple myeloma and Revlimid, a less toxic thalidomide derivative, to treat myelodysplastic syndromes, multiple myeloma, and mantle cell lymphoma. Acquisitions have brought MDS drug Vidaza, T-cell lymphoma drug Istodax, and cancer drug Abraxane. The firm's first immunology drug, Otezla, was approved in the U.S. in 2014. Recent acquisitions of Juno and Impact bring additional drugs for Celgene's blood cancer pipeline.